Caas Capital Management LP Altimmune, Inc. Transaction History
Caas Capital Management LP
- $552 Million
- Q4 2024
Shares
2 transactions
Others Institutions Holding ALT
# of Institutions
208Shares Held
39.5MCall Options Held
1.94MPut Options Held
1.38M-
Black Rock Inc. New York, NY5.32MShares$34.2 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN5.25MShares$33.8 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.43MShares$28.5 Million0.0% of portfolio
-
State Street Corp Boston, MA3.47MShares$22.3 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$17.7 Million1.49% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $315M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...